Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia
Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Sylvie Freeman(University of Birmingham), Shouhao Zhou(Pennsylvania State University), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Christopher S. Hourigan(National Heart Lung and Blood Institute), Chenqi Fu(Pennsylvania State University), Donald A. Berry(Berry & Associates (United States)), Hyunsoo Hwang(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Xinyue Qi(Pennsylvania State University), Graciela Nogueras González(The University of Texas MD Anderson Cancer Center), Roland B. Walter(Rafael Advanced Defense Systems (Israel))
Cited by 380
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k